Biolife breast cancer vaccine validated in journal

Biolife Science has announced that the strategy it has taken to develop its breast cancer vaccine has been endorsed in a scientific journal.

The company’s HER-Vaxx B cell peptide vaccine was featured in a recent peer-reviewed article published in the journal Breast Cancer Research and Treatment.

The article examines several classes of breast cancer vaccines acting as delivery systems for HER2/neu, an oncogenic protein that acts as a tumour antigen. It concludes that among these classes, the generation of peptide vaccines to which HER-Vaxx belongs is currently the simplest and most cost-effective.

More complex DNA vaccines are not yet sufficiently developed for clinical application, while T-cell epitope vaccines present limitations due to their human leukocyte antigen (HLA) restriction. Peptide vaccines lack this HLA restriction.

HER-Vaxx has been tested in a phase I human trial, achieving B-cell immunity in 10 women with breast cancer, and has been validated in human cancers in lab tests.

Biolife Science last month announced plans for a reverse takeover of ASX-listed Acuvax (ASX:ACU), to be followed by an up to $5 million placement to help fund a phase II trial of HER-Vaxx.

The company aims to file an Investigational New Drug (IND) application with the US FDA in the third quarter.

If the reverse takeover and subsequent placement goes through as intended, Biolife Science will have a market cap of $11.3 million.